Bionano Genomics (BNGO) Payables (2017 - 2026)

Bionano Genomics has disclosed Payables across 10 years of filings, most recently posting $15.2 million for Q1 2026.

• Payables for Q1 2026 came in at $15.2 million, down 22.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.2 million (down 22.39% YoY), and the FY2025 annual result was $15.6 million, down 43.02% from the prior year.
• Payables came in at $15.2 million for Q1 2026 at Bionano Genomics, down from $15.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $80.2 million in Q4 2023 to a low of $6.6 million in Q1 2022.
• The 5-year median for Payables is $15.8 million (2023), against an average of $21.3 million.
• Across the five-year window, Payables jumped 539.76% in 2023 and plunged 65.92% in 2024, its largest moves.
• Bionano Genomics' Payables stood at $12.5 million in 2022, then surged by 539.76% to $80.2 million in 2023, then slumped by 65.92% to $27.3 million in 2024, then plunged by 43.02% to $15.6 million in 2025, then decreased by 2.28% to $15.2 million in 2026.
• The last three Payables figures came in at $15.2 million (Q1 2026), $15.6 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.